Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 8, 2010, Pages 611-614

  Koh, Kyung Nam ^a   Park, Meerim ^a   Kim, Bo Eun ^a   Im, Ho Joon ^a   Seo, Jong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

deferasirox; hematopoietic recovery; iron chelation therapy; severe aplastic anemia

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; DEFERASIROX; FERRITIN; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

APLASTIC ANEMIA; ARTICLE; CASE REPORT; CHELATION THERAPY; CHILD; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FERRITIN BLOOD LEVEL; HEMATOPOIESIS; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; PANCYTOPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TRANSFUSION; BLOOD; BLOOD TRANSFUSION; DRUG EFFECT; HOSPITALIZATION;

ANEMIA, APLASTIC; BENZOIC ACIDS; BLOOD TRANSFUSION; CHILD; HEMATOPOIESIS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; SEVERITY OF ILLNESS INDEX; TRIAZOLES;

EID: 78349260844     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e8854d     Document Type: Article

References (20)

1. Nick H. Iron chelation, quo vadis? Curr Opin Chem Biol. 2007; 11:419-423. (Pubitemid 47302851)
2. Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9:2391-2402.
3. Lee JW. Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. Int J Hematol. 2008;88:16-23.
4. Kurre P, Johnson FL, Deeg HJ. Diagnosis and treatment of children with aplastic anemia. Pediatr Blood Cancer. 2005;45: 770-780. (Pubitemid 41416486)
5. Marsh JH, Hundert M, Schulman P. Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol. 1990;76:148-149. (Pubitemid 20326810)
6. Sane A, Manzi S, Perfect J, et al. Deferoxamine treatment as a risk factor for zygomycete infection. J Infect Dis. 1989;159: 151-152. (Pubitemid 19022014)
7. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94:288-299. (Pubitemid 26247987)
8. Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol. 1996;51:243-244.
9. Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008; 120:70-74.
10. Di Tucci AA, Murru R, Alberti D, et al. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol. 2007;78: 540-542. (Pubitemid 46753589)
11. Okabe H, Suzuki T, Omori T, et al. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. Rinsho Ketsueki. 2009;50:1626-1629.
12. Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci. 2008;23:320-323.
13. Bergmann AK, Tamary H, Neufeld EJ. Remission from transfusion-dependence in a patient with congenital dyserythropoietic anemia (CDA) and increased intensity of iron chelation. Pediatr Blood Cancer. 2009;53:1167-1168.
14. Taher AT, Musallam KM, Koussa S, et al. Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy. Ann Hematol. 2009;88:1263-1264.
15. Weinberg K. Novel uses of deferoxamine. Am J Pediatr Hematol Oncol. 1990;12:9-13. (Pubitemid 20132084)
16. Bierer BE, Nathan DG. The effect of desferrithiocin, an oral iron chelator, on T-cell function. Blood. 1990;76:2052-2059.
17. Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met. 1990;3:183-187.
18. Louache F, Testa U, Pelicci P, et al. Regulation of transferrin receptors in human hematopoietic cell lines. J Biol Chem. 1984;259:11576-11582. (Pubitemid 14010050)
19. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNAbinding activity: implications for models of hypoxia signal transduction. Blood. 1993;82:3610-3615.
20. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood. 2009;114: 5251-5255.